Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cogent Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Cogent Biosciences, Inc.’s stock price such as:

• Cogent Biosciences, Inc.’s current stock price and volume
• Why Cogent Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for COGT from analysts
• COGT’s stock price momentum as measured by its relative strength

About Cogent Biosciences, Inc. (COGT)

Before we jump into Cogent Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Want to learn more about Cogent Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cogent Biosciences, Inc..

Cogent Biosciences, Inc.’s Stock Price as of Market Close

As of May 14, 2025, 12:45 PM, CST, Cogent Biosciences, Inc.’s stock price was $4.880.

Cogent Biosciences, Inc. is down 2.2% from its previous closing price of $4.990.

During the last market session, Cogent Biosciences, Inc.’s stock traded between $4.740 and $5.170. Currently, there are approximately 113.38 million shares outstanding for Cogent Biosciences, Inc..

Cogent Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cogent Biosciences, Inc. Stock Price History

Cogent Biosciences, Inc.’s (COGT) price is currently down 6.33% so far this month.

During the month of May, Cogent Biosciences, Inc.’s stock price has reached a high of $5.890 and a low of $4.551.

Over the last year, Cogent Biosciences, Inc. has hit prices as high as $12.610 and as low as $3.720. Year to date, Cogent Biosciences, Inc.’s stock is down 37.44%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cogent Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2025, there were 3 analysts who downgraded Cogent Biosciences, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cogent Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cogent Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cogent Biosciences, Inc. (COGT) by visiting AAII Stock Evaluator.

Relative Price Strength of Cogent Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2025, Cogent Biosciences, Inc. has a weighted four-quarter relative price strength of -15.60%, which translates to a Momentum Score of 16 and is considered to be Very Weak.

Want to learn more about how Cogent Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cogent Biosciences, Inc. Stock Price: Bottom Line

As of May 14, 2025, Cogent Biosciences, Inc.’s stock price is $4.880, which is down 2.2% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cogent Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.